EMA Approval: Lenacapavir (Sunlenca), a First-In-Class HIV Capsid Inhibitor

In August 2022, the European Medicines Agency granted Marketing Authorization to lenacapavir (Sunlenca), the first-in-class bi-annually dosed HIV capsid inhibitor indicated for multidrug-resistant HIV-1 infection.

This Premium deep dive into Sunlenca includes:

• the industry context

• the clinical data

• the target rationale

• the mechanism of action

• the drug’s origins

Lenacapavir (Sunlenca), chemical structure

See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.